Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 13/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 10/20 | 0.46 |
| ▸ | MAPK13 | O15264 | 8/20 | 0.46 |
| ▸ | MAPK12 | P53778 | 8/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.35 |
| ▸ | NLK | Q9UBE8 | 2/20 | 0.35 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.35 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | CDK9 | P50750 | 1/20 | 0.32 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.32 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.32 |
| ▸ | ALPL | P05186 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4467184 | 0.91 | MAPK14 (0.41) | MAPK14MAPK11MAPK13MAPK12KCNH2 | |
| SCHEMBL4470456 | 0.90 | MAPK14 (0.42) | MAPK14MAPK11MAPK13MAPK12KCNH2 | |
| SCHEMBL4471367 | 0.89 | SCN9A (0.47) | MAPK14MAPK11MAPK13MAPK12KCNH2 | |
| Dilmapimod SCHEMBL29372394 | 0.86 | MAPK14 (0.47) | MAPK14MAPK11MAPK13MAPK12KCNH2 | |
| SCHEMBL4473445 | 0.86 | MAPK14 (0.45) | MAPK14MAPK11MAPK13MAPK12KCNH2 | |
| Dilmapimod SCHEMBL1065268 | 0.86 | MAPK14 (0.47) | MAPK14MAPK11MAPK13MAPK12KCNH2 | |
| Dilmapimod SCHEMBL29379709 | 0.86 | MAPK14 (0.47) | MAPK14MAPK11MAPK13MAPK12KCNH2 | |
| Dilmapimod SCHEMBL29528002 | 0.86 | MAPK14 (0.47) | MAPK14MAPK11MAPK13MAPK12KCNH2 | |
| SCHEMBL1066098 | 0.84 | MAPK14 (0.41) | MAPK14MAPK11MAPK13MAPK12KCNH2 | |
| SCHEMBL3223931 | 0.83 | SCN9A (0.41) | MAPK14MAPK11MAPK13MAPK12KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629350-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-08 | — | — | US | claimed |
| EP-1499320-B1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2007-08-22 | — | — | EP | claimed |
| US-20060293348-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-12-28 | — | — | US | claimed |
| US-7629350-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-08 | — | — | US | disclosed |
| US-7629350-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-08 | — | — | US | disclosed |
| US-7629350-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-08 | — | — | US | disclosed |
| EP-1499320-B1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2007-08-22 | — | — | EP | disclosed |
| EP-1499320-B1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2007-08-22 | — | — | EP | disclosed |
| US-20060293348-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-12-28 | — | — | US | disclosed |
| EP-1499320-A4 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2006-05-17 | — | — | EP | disclosed |
| EP-1499320-A1 | NOVEL COMPOUNDS | SmithKline Beecham Corporation (US) | 2005-01-26 | — | — | EP | disclosed |
| WO-2003088972-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293348-A1 | Novel compounds | MAPKAPK2, CREBBP, CDC42BPB | MAPK14 42/4885MAPK11 94/4885MAPK13 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.